Shots:

• The companies collaborated to evaluate NKT2152 (HIF2α inhibitor) + palbociclib (CDK4/6 inhibitor) and sasanlimab (PD-1 inhibitor) for the treatment of advanced ccRCC
• NiKang will sponsor the study while Pfizer will co-fund the trials and supply its therapies at no cost to NiKang. Additionally, both companies will form a joint development committee to oversee the collaboration
• NKT2152 is currently being evaluated in a P-I/II dose escalation and expansion trial to assess safety, tolerability, PK, PD, and clinical activity in patients with advanced ccRCC. The combination studies will start when an appropriate dose is identified

/ article | Ref: Businesswire | Image: The Wall Street Journal